COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies - Coronavirus Disease 2019 Sector Forecast

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies - Coronavirus Disease 2019 Sector Forecast



The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact Small and Mid Bio/Pharma Companies.

Scope

- This PowerPoint based report gives an important expert analysis on how the developement of vaccines and therapeutics for COVID-19 has been approached by Small and Mid Cap Bio/Pharma Companies.
- Findings are based on the industrys most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Reasons to Buy

- An overview of how Small and Mid Cap Bio/Pharma Companies have approached the developemnt of vaccines and therapeutics for the COVID-19 pandemic.

1 COVID-19 Pipeline of Small and Mid-Cap Companies
1.1 COVID-19 Pipeline of Small and Mid-Cap Companies
1. 2 Analysis of COVID-19 Pipeline by Phase and Type
1.3 Analysis of COVID-19 Pipeline by Market Cap
2 Vaccine Development by Small and Mid-Cap Companies
2.1 COVID-19 Vaccine Pipeline by Phase and Molecule Subtype
2.2 Highest Development Phase COVID-19 Vaccine Pipeline
3 Therapeutic Development by Small and Mid-Cap Companies
3.1 COVID-19 Therapeutic Pipeline by Phase and Molecule Type
3.2 COVID-19 Biologic Therapeutic Pipeline by Phase and Molecule Subtype
3.3 Highest Development Phase COVID-19 Therapeutic Pipeline
4 COVID-19 Deals
4.1 COVID-19-related Partnership Agreements with Small and Mid-Cap Companies
4.2 COVID-19-related Licensing Agreements with Small and Mid-Cap Companies
Key Findings
Appendix
6.1 Glossary
6.2 Methodology
6.3 Related Reports
6.4 About the Authors
6.5 About GlobalData
6.6 Contact Us

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is

USD 1495 View Report

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the

USD 2495 View Report

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class ProductsAn allergy or allergic disease is a condition that arises from

USD 6995 View Report

Gastrointestinal Disorders: Innovative Pipeline Offers Potential for First Approved Therapies in NASH and Celiac Disease

Gastrointestinal Disorders: Innovative Pipeline Offers Potential for First Approved Therapies in NASH and Celiac DiseaseThe burden of disease associated with gastrointestinal disorders is considerable with many of these disorders being

USD 6995 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available